Bryostatin - Neurotrope BioScience

Drug Profile

Bryostatin - Neurotrope BioScience

Alternative Names: Bryostatin-1 - Neurotrope

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience
  • Developer Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience; Rettsyndrome.org
  • Class Antineoplastics; Macrocyclic compounds
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Fragile X syndrome; Niemann-Pick disease type C; Rett syndrome

Most Recent Events

  • 22 Nov 2016 Neurotrope completes enrolment in its phase II trial for Alzheimer's disease in USA
  • 18 Nov 2016 Neurotrope plans to initiate a phase II open-label extension trial in Alzheimer's disease
  • 15 Aug 2016 Neurotrope BioScience submits an amended protocol with the US FDA, for a phase IIb trial in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top